BRUSSELS, Aug 27 (Reuters) - The European Commission has paid 336 million euros ($396 million) to secure at least 300 million doses of the potential COVID-1 vaccine being developed by British drug maker AstraZeneca, a spokesman said on Thursday.
Brussels signed the deal on behalf of EU states for the supply of at least 300 million doses of its COVID-19 vaccine candidate. It has an option for a further 100 million, the spokesman said.
“We cannot indicate at this stage the specific pricing per dose. However, a significant part of the overall costs are funded by a contribution from the overall ESI funding for vaccines,” he said, referring to the bloc’s so-called emergency support instrument.
($1 = 0.8479 euros)
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.